193 related articles for article (PubMed ID: 8427991)
1. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?
Ringdén O; Horowitz MM; Sondel P; Gale RP; Biggs JC; Champlin RE; Deeg HJ; Dicke K; Masaoka T; Powles RL
Blood; 1993 Feb; 81(4):1094-101. PubMed ID: 8427991
[TBL] [Abstract][Full Text] [Related]
2. Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies.
von Bueltzingsloewen A; Belanger R; Perreault C; Bonny Y; Roy DC; Lalonde Y; Boileau J; Kassis J; Lavallee R; Lacombe M
Blood; 1993 Feb; 81(3):849-55. PubMed ID: 8427977
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.
Hahn T; McCarthy PL; Zhang MJ; Wang D; Arora M; Frangoul H; Gale RP; Hale GA; Horan J; Isola L; Maziarz RT; van Rood JJ; Gupta V; Halter J; Reddy V; Tiberghien P; Litzow M; Anasetti C; Pavletic S; Ringdén O
J Clin Oncol; 2008 Dec; 26(35):5728-34. PubMed ID: 18981462
[TBL] [Abstract][Full Text] [Related]
5. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry.
Gale RP; Horowitz MM
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():94-7. PubMed ID: 2390646
[TBL] [Abstract][Full Text] [Related]
6. T-cell depletion of HLA-identical transplants in leukemia.
Marmont AM; Horowitz MM; Gale RP; Sobocinski K; Ash RC; van Bekkum DW; Champlin RE; Dicke KA; Goldman JM; Good RA
Blood; 1991 Oct; 78(8):2120-30. PubMed ID: 1912589
[TBL] [Abstract][Full Text] [Related]
7. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
[TBL] [Abstract][Full Text] [Related]
8. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
[TBL] [Abstract][Full Text] [Related]
9. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia.
Storb R; Pepe M; Deeg HJ; Anasetti C; Appelbaum FR; Bensinger W; Buckner CD; Cliff RA; Doney K; Hansen J
Blood; 1992 Jul; 80(2):560-1. PubMed ID: 1627810
[No Abstract] [Full Text] [Related]
11. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial.
Locatelli F; Zecca M; Rondelli R; Bonetti F; Dini G; Prete A; Messina C; Uderzo C; Ripaldi M; Porta F; Giorgiani G; Giraldi E; Pession A
Blood; 2000 Mar; 95(5):1572-9. PubMed ID: 10688810
[TBL] [Abstract][Full Text] [Related]
12. A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy.
Atkinson K; Biggs J; Concannon A; Dodds A; Young S; Wilson F; Ashby M; Downs K
Aust N Z J Med; 1991 Dec; 21(6):850-6. PubMed ID: 1818544
[TBL] [Abstract][Full Text] [Related]
13. Fractionated TBI and methotrexate-cyclosporin do not seem to increase relapses in BMT for first chronic phase CML patients: results of a single centre study.
López J; Vázquez L; Serrano F; Kassack JJ; Figuera A; Steegmann JL; Cámara R; Lamana M; Ferro T; Fernández-Villalta MJ
Bone Marrow Transplant; 1992 Sep; 10(3):235-9. PubMed ID: 1422477
[TBL] [Abstract][Full Text] [Related]
14. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
[TBL] [Abstract][Full Text] [Related]
15. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.
Nademanee A; Schmidt GM; Parker P; Dagis AC; Stein A; Snyder DS; O'Donnell M; Smith EP; Stepan DE; Molina A
Blood; 1995 Aug; 86(3):1228-34. PubMed ID: 7620176
[TBL] [Abstract][Full Text] [Related]
16. Identical-twin bone marrow transplants for leukemia.
Gale RP; Horowitz MM; Ash RC; Champlin RE; Goldman JM; Rimm AA; Ringdén O; Stone JA; Bortin MM
Ann Intern Med; 1994 Apr; 120(8):646-52. PubMed ID: 8135448
[TBL] [Abstract][Full Text] [Related]
17. De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival.
Wagner JL; Seidel K; Boeckh M; Storb R
Biol Blood Marrow Transplant; 2000; 6(6):633-9. PubMed ID: 11128814
[TBL] [Abstract][Full Text] [Related]
18. Graft-versus-leukemia reactions after bone marrow transplantation.
Horowitz MM; Gale RP; Sondel PM; Goldman JM; Kersey J; Kolb HJ; Rimm AA; Ringdén O; Rozman C; Speck B
Blood; 1990 Feb; 75(3):555-62. PubMed ID: 2297567
[TBL] [Abstract][Full Text] [Related]
19. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
[TBL] [Abstract][Full Text] [Related]
20. [The analysis of leukemic relapse after allogeneic bone marrow transplantation].
Yoshimura M; Yoshida H; Matsunashi T; Hidaka S; Kobayashi M; Yoshida S; Tominaga N; Tejima H; Hiraoka A; Nakamura H
Rinsho Ketsueki; 1991 Nov; 32(11):1433-8. PubMed ID: 1758050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
